Macular Edema, Retinal Vein Occlusion
Conditions
Keywords
Ultra-wide field fundus fluorescein angiography, ischemic index, leakage index
Brief summary
This study mainly observed the ischemic index and vascular leakage index changes on ultra-wide field fluorescence angiography after anti-VEGF treatment , and whether these changes correlated with treatment efficacy in patients with macular edema secondary to retinal vein occlusion.
Detailed description
Ultra-wide field fluorescence angiography can clearly observe the peripheral retina. This study mainly observes the ischemic index and vascular leakage index changes on UWFA after anti-VEGF treatment and evaluates these changes associated with treatment efficacy in patients with macular edema secondary to retinal vein occlusion.
Interventions
Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML
DEVICEUltra-wide Fluorescein Angiography
Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina
Sponsors
Renmin Hospital of Wuhan University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female aged 18 years or older 2. Macular edema secondary to CRVO,BRVO or HRVO 3. Duration of RVO not more than 4 months 4. Naïve patients. Patient with previous RVO (more than 12 months before the inclusion date) completely resolved (normalization of visual acuity and fundus examination) and who have experienced a recurrence of RVO are also considered naive 5. Patient who agrees to participate in the study and who has given his/her written, informed consent
Exclusion criteria
1. Patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period 2. Active or suspected ocular or periocular infection 3. Active severe intraocular inflammation 4. RVO complicated with neovascularization 5. Patient who has previously undergone laser panretinal photocoagulation, grid-laser or photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study eye 6. Patient already included in the study for the treatment of the fellow eye 7. Pregnant or breastfeeding woman 8. Lack of effective contraception for women of childbearing age 9. Patient taking part in an interventional study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in vascular leakage index in different retinal area | Baseline and 1,2,3,4,6,9 and 12 months | Change in vascular leakage index in different retinal area from baseline to 1,2,3,4,6,9 and 12 months |
| Change in non-perfused areas in different retinal area | Baseline and 1,2,3,4,6,9 and 12 months | Change in non-perfused areas in different retinal area from baseline to 1,2,3,4,6,9 and 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in best corrected visual acuity | Baseline and 1,2,3,4,6,9 and 12 months | Change in best corrected visual acuity from baseline to 1,2,3,4,6,9 and 12 months |
| Change in central macular thickness | Baseline and 1,2,3,4,6,9 and 12 months | Change in central macular thickness from baseline to1,2,3,4,6,9 and12 months |
Countries
China
Contacts
Primary ContactCZ Chen, PHD
Outcome results
None listed